Viking faces Ligand lawsuit over VK2809/VK0214 rights as Phase 3 trials advance

Filed July 29, 2026 · Period ending June 30, 2026 · Compared to 10-Q Jul 23, 2025 · ~2 min read

Key Changes

• high

  Ligand purported to terminate Viking's license to VK2809 and VK0214 in April 2026 and filed suit seeking return of intellectual property. Viking filed a cross-complaint asserting the termination is invalid. If Ligand prevails, Viking loses the right to develop or commercialize both TR-Beta candidates.

  Legal Proceedings verify on EDGAR →
• high

  Both VK2735 Phase 3 VANQUISH studies completed enrollment (VANQUISH-1 in November 2025, VANQUISH-2 in March 2026). Oral VK2735 Phase 2 showed up to 12.2% weight loss with favorable safety; Phase 3 oral trials planned for Q4 2026.

  MD&A: VK2735 Development verify on EDGAR →
• high

  R&D expenses surged 162% YoY to $252,000 for the six months ended June 30, 2026, driven by VK2735 Phase 3 trial costs and manufacturing scale-up. Operating loss widened 78% to $132.6M.

  MD&A: Operating Results verify on EDGAR →